A Dose Escalation of Gimatecan Administered Orally to Japanese Patients With Advanced Solid Tumor.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This study assesses the tolerability, safety, efficacy and pharmacokinetics of gimatecan in Japanese patients. Gimatecan is administered orally for five consecutive days, every 28 days, to adult patients with advanced solid tumors who have progressed despite standard therapy or for whom standard systemic therapy does not exist.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
20 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with histological or cytological confirmed advanced solid tumors, which have progressed despite standard therapy or for whom no standard therapy exists.
Life expectancy of at least 3 months
Adequate hematological parameters
No major impairment of renal and hepatic function
Gastrointestinal dysfunction, such as gastrectomy and malabsorption syndrome that could alter absorption.
Patients who have received any investigational compound within the past 28 days.
Patients with other antineoplastic therapy within the last 28 days.
Patients known to be HIV or hepatitis virus positive, or patients with the presence of active or suspected acute or chronic uncontrolled infection
Patients with a history of allergies to the camptothecin family drug.
Other protocol-defined inclusion/exclusion criteria may apply